2021 ASCO Review on AntiHER2 Antibody-Drug Conjugates in BC: DESTINY…

Guy Jerusalem

Trastuzumab Deruxtecan for HER2+ MBC With Brain Mets: DESTINY-Breast…

Nicole Williams

ASCO 2021 Comparison of Standard Anti-HER2 Directed Approaches in MB…

Hans-Christian Kolberg

Triplet Targeting Combination in HR+/HER2+ BC: Understanding Signali…

University of Colorado Cancer Center

E. Shagisultanova

Case Study Discussion on HER2+ MBC: Trastuzumab Deruxtecan in Heavil…

2021 Virtual Best of Breast

P. Anderson, S. Badve, E. Hamilton, R. L. Mahtani

Advances in HER2+ BC: Overview of Current Data

2021 Community Oncology Conference

J. O'Shaughnessy

Management of HER2+ MBC: Surveying the Data for ADC, TKI, and Novel …

Total Health

T. Traina, L. Carey

Colorado University Highlights on BC Research: Inhibiting Tumor Cell…

University of Colorado Cancer Center

H. Ford, J. Richer, T. Lyons

Ongoing Therapy Escalation Trials in HER2+ BC: COMPASSHER2 Data, Tre…

Total Health

J. Meisel, H. Soliman

HER2+ Breast Cancer: Optimizing Quality of Life

Virginia Kaklamani